Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ: RGNX )

7.300 -0.020 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases. 
Via Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts
Via Benzinga
Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Where Regenxbio Stands With Analysts
Via Benzinga
5 Analysts Have This To Say About Regenxbio
Via Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
Via Benzinga
Workday, Apollo Global To Join S&P 500 Index In Quarterly Balance
They'll join the index before the open on Dec. 23 as part of a quarterly rebalance. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
What's Going On With REGENXBIO Shares Monday?
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy. 
Via Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Assessing Regenxbio: Insights From 5 Financial Analysts
Via Benzinga
Where Regenxbio Stands With Analysts
Via Benzinga
Assessing Regenxbio: Insights From 4 Financial Analysts
Via Benzinga
Evaluating Regenxbio: Insights From 9 Financial Analysts
Via Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
Why Is Clearside Biomedical Stock Gaining Today?
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... 
Via Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. 
Via Benzinga
Exposures Product Safety
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. 
Via Investor's Business Daily
Where Regenxbio Stands With Analysts
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
Via Benzinga
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
Via Investor's Business Daily
Exposures Product Safety
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
RGNX stock results show that Regenxbio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
The threat is still emerging, but it could be significant. 
Via The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.